Thanks to homegrown talent, A-list investors, and new owner Willow Bay, the women’s soccer team has won the industry’s hearts ...

IU's alumni network is full of trailblazers, with names like Suzanne Collins and Mark Cuban often getting most of the ...

By Twesha Dikshit and Ragini Mathur (Reuters) -European shares posted their biggest weekly gain in twelve weeks on Friday, as banking stocks continued to drive the benchmark index upwards, while ...

Eli Lilly said a third late-stage study of its experimental anti-obesity pill hit its key goals, paving the way for the drugmaker to begin regulatory submissions.

Eli Lilly and Co. (NYSE:LLY) on Tuesday released topline results from the Phase 3 ATTAIN-2 trial, evaluating oral ...

In a study of more than 1,600 adults with type 2 diabetes, those who received the highest dose of orforglipron on average shed 10.5% of their weight.

Pharmaceutical giant Eli Lilly said it will now move “with urgency” toward getting regulatory approval for orforglipron.

Viking Therapeutics reported positive Phase 2 results for VK2735, showing significant weight loss and safety in obesity ...

Eli Lilly & Co.’s experimental pill helped patients shed roughly 11% of their body weight, about 25 pounds, in a late-stage study that sets the stage for a new entrant to the obesity market ...

Viking Therapeutics, Inc. (NASDAQ:VKTX) is pressing ahead in the weight-loss drug race with the launch of its Phase 2 VENTURE ...

The fast-selling GLP-1 drug matched Lilly's older medicine Trulicity in a closely watched cardiovascular outcomes trial, while showing greater weight loss and blood sugar control.

Eli Lilly and Novo Nordisk are expected to price their new obesity pills in line with existing injections, as analysts cite affordability, supply capacity, and growing demand in the U.S. market.